| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Amivantamab-vmjw (Rybrevant) and Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro) | 2026-03-02 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Inebilizumab-cdon (Uplizna) | 2026-03-02 |
| BCBS Highmark Penn Medicare Advantage | Inebilizumab-cdon (Uplizna) | 2026-03-02 |
| BCBS Highmark NY and West NY | Non-Surgical Management of Nasal Airway Obstruction | 2026-03-02 |
| BCBS Highmark NY and West NY | GI Effects Comprehensive Stool Profile | 2026-03-02 |
| BCBS Highmark NY and West NY | Mosunetuzumab-axgb (Lunsumio) and mosunetuzumab-axgb (Lunsumio Velo) | 2026-03-02 |
| BCBS Highmark NY and West NY | Inebilizumab-cdon (Uplizna) | 2026-03-02 |
| BCBS Highmark Delaware | Partial Hospitalization Programs | 2026-03-02 |
| BCBS Highmark Delaware | Intensive Outpatient Programs | 2026-03-02 |
| BCBS Highmark Delaware | Non-Surgical Management of Nasal Airway Obstruction | 2026-03-02 |